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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre and any of their employees. Sections of 
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TPP  Target Product Profile 
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The disease, etiology, epidemiology and impact 
Peste des petits ruminants (PPR) is an acute contagious viral disease of sheep and goats. PPR is caused by a 
Morbillivirus in the family Paramyxoviridae. The virus has a lipid envelope which contains the fusion (F) and 
haemagglutinin (H) glycoproteins. All virus strains belong to a single serotype, but the different strains have 
been grouped in 4 distinct lineages.Goats and sheep are the primary hosts for PPRV with few reports in camels. 
Cattle, buffalo and pigs develop subclinical infection but are not capable of excreting the virus and are not 
considered epidemiologically relevant. Young animals are most severely affected, and goats more than sheep. In 
its peracute form animals are found dead. Clinical signs include fever, depression, loss of appetite, and clear 
nasal discharge. This nasal discharge becomes mucopurulent and can result in a profuse catarrhal exudate which 
crusts and occludes the nostrils causing respiratory distress. There is congestion of the conjunctiva, and 
sometimes profuse catarrhal conjunctivitis. Ulcers are formed on the lower gums, dental pad, hard palate, 
cheeks and tongue. Necrotic stomatitis is common. Severe diarrhoea develops in some animals. Pregnant 
animals may abort. Morbidity rate in susceptible populations can reach 90–100%. Mortality rates vary among 
susceptible animals but can reach 50–100% in more severe instances. The disease is transmitted though aerosol 
or animal excretions. PPR threatens more than 1.7 billion of sheep and goats, as well as the livelihoods, and food 
security of more than 330 million people. It is estimated that the direct annual losses due to PPR are between 
USD 1.2 and 1.7 billion. The estimated current expenditure on PPR vaccination ranges between USD 270 and 380 
million. The annual impact of PPR may be valued at between USD 1.45 and 2.1 billion per year.    
 
Incidence / Prevalence  
Since its first identification in the early 1940s in Côte d’Ivoire, PPR has steadily expanded. It occurs now in most 
African countries from North Africa to Tanzania.  Also in large parts of Central Asia, South Asia and East Asia. It is 
present in the Arabian Peninsula, and nearly all Middle Eastern countries. Of the focus countries, Myanmar and 
South Africa have OIE official freedom status. The disease is not present in Southern Africa, but there have been 
a couple of outbreaks in Zambia and there are fears of the disease spreading from the neighbouring countries. 
 
Diagnostics  
The OIE Terrestrial Manual described methods for the agent identification include virus isolation, 
immunocapture ELISA, counter immunoelectrophoresis and agar gel immunodiffusion.  Polymerase chain 
reaction (PCR) may also be used. The serological tests routinely used are the virus neutralization test and the 
competitive ELISA.  A field test, a lateral flow device using an immunocapture test has been relatively recently 
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commercialized. A Luciferase Immunoprecipitation System (LIPS) for the rapid detection of antibodies against 
PPR has also been recently developed.  
 
Control  
Antivirals have been suggested, but the generation of escape mutants is of concern. The standard disease 
control measures of quarantine, movement control, sanitary slaughter, and cleaning and disinfection are applied 
when the disease enters or re-appears in an area. The virus is susceptible to most disinfectants.  Vaccines are 
used where the disease is established and it provides good immunity. Following the success of Rinderpest 
eradication, and in response to calls from member countries, FAO and OIE have taken the lead in developing a 
Global Strategy for the control and eradication of PPR. They believe PPR can be eradicated within 15 years, 
provided it is adequately resourced and well-coordinated, with the political commitment and participation of 
key partners.   
 
Current vaccines for PPR 
The current available PPR vaccines, are cell culture-attenuated strains of natural PPRV. The first vaccine, the 
Nigeria 75/1 has been used extensively in Africa and the Middle East, but other strains have also been 
developed, especially in India, where Sungri/96 is preferred.  The OIE says that normally, the minimum 
immunising dose is 100x the lowest dose of vaccine virus able to induce 50% immunising response, and for 
Nigeria 75/1, the minimum titre is 102.5 TCID50.  The vaccine is safe including in pregnant animals, and 
efficacious. It provides strong protective immunity for 3-5 years, enough to cover the lifespan of the small 
ruminants. It is effective against viruses from all lineages.  
 
Research & Potential new vaccines and the way forward 
The main challenges or the current vaccines are the thermostability and the DIVA capability. To improve the 
thermotolerance, two strategies have been used. One is by using different formulations and cycles during 
lyophilisation.  The other one is the development of thermo-adapted strains. There are many publications or 
communications, each claiming that their method is the most appropriate. A comparison has been attempted in 
Table 8, but is not complete as information is not always clear or comparable.  A priority would be the 
independent validation of the different techniques, starting from the same material and using the same 
equipment. This is something that PANVAC has been wanting to do for some time. The thermo-adapted strains 
developed at IVRI in India, are also very promising, and further validation might be warranted.  
As for the DIVA vaccines, many strategies have been used. Various groups have been working on recombinant 
adenovirus expressing PPR. They are very promising candidates, but they need to be evaluated long term, as to 
confirm the life-long immunity with a single dose. Other strategies include the use of modified vaccinia virus 
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Ankara (requires 2 doses), virus like particles produced in baculovirus systems (have challenges for purification), 
recombinant fowlpox expressing PPR (poor response), DNA vaccines or plant expressed PPR proteins, both of 
which need further validation.  
Combined vaccines are an asset, as one of the main costs of vaccination is logistics.  It has been demonstrated 
that PPR and Sheep and Goat pox can be combined, and a commercial product already exists as a combination in 
Morocco. Recently this combination vaccine has started to be used in other African countries.Combined DIVA 
vaccines have double attraction. A very promising candidate is a Capripoxvirus expressing the PPR proteins, but 
has recently been shown to induce only partial protection for PPR in the presence of pre-exisiting immunity to 
the vector.  With the use of reverse genetics, a recombinant PPR virus expressing Foot and Mouth Disease (FMD) 
protein has demonstrated protection from challenge with FMD virus, but is yet to be evaluated for challenge to 
PPR. 
 
Commercial manufacturing of PPR vaccines 
There are many commercial manufacturers of PPR vaccines in Asia and Africa.  Their main interest at the 
moment, is improving thermotolerance of the current vaccine.  
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Clinical disease overview 
Etiology & Epidemiology 
The infective agent was first considered a variant 
of rinderpest virus adapted to small ruminants, but 
was later shown to be antigenically and genetically 
distinct. PPR is caused by a Morbillivirus in the 
family Paramyxoviridae. It is related to rinderpest, 
measles and canine distemper.  PPRV is a 
pleomorphic particle (Figure 1) with a lipid 
envelope enclosing a ribonucleoprotein core that 
contains the genome, a single strand of RNA with 
negative polarity.  The genome length of PPR virus 
(PPRV) is 15,948 nucleotides. There are six genes, 
or transcription units (Figure 1). The viral genes 
encode the nucleocapsid (N) protein, the 
phosphoprotein (P), the matrix protein (M), the 
fusion (F) and haemagglutinin (H) membrane 
glycoproteins, and the large protein (L), which is 
the viral polymerase. The P gene also encodes the 
three accessory proteins V, W and C, which are 
sometimes referred to as non-structural, although 
it is not conclusively proven that they are not part 
of the virion. They are not required for the 
replication and assembly of the virus. The P and L 
proteins together form the functional viral RNA 
polymerase. The F and H proteins are found in the 
viral envelope, projecting to the outside of the 
virion and the infected cell. The H protein is 
responsible for binding to the host cell receptor, 
Virus structure 
 
The PPRV glycoproteins (F and H) are embedded within the 
viral envelope.  The M protein lines the inner surface of the 
virus envelope. The ribonucleoprotein complex is composed of 
N, P and L proteins in association with the RNA genome.  




Figure 1:  Schematic diagram of Peste des petits 
ruminants virion structure. 
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whereas the F protein allows the viral envelope to fuse with the host cell envelope, transferring the 
nucleocapsid to the host cell cytoplasm. The M protein plays an as-yet not understood role in virus budding and 
structure [1]. 
 
All PPR virus strains belong to a single serotype, but the different strains have been grouped into four distinct 
lineages, with lineages I and II occurring in West Africa, lineage III in East Africa, the Middle East and southern 
India, and lineage IV in Asia. These lineages are based on sequence differences on a short (approximately 300 
bases) specific section of the viral F gene or N gene. The utility of lineage identification lies in the information it 
provides on the probable origin of the virus causing a new outbreak. PPRV lineage IV has been found in recent 
years in sub-Saharan Africa, and appears to be displacing viruses of the so-called “African” lineages (I–III). The 
disease occurs in a band that spreads across Africa between the equator and the Sahara, through the Arabian 
Peninsula, the Middle East, south-west Asia and India. China first reported the disease in 2007 and it spread into 




Figure 2: Global spread of PPR from its first detection in 1942-2014, including lineage distribution. Source: 
Parida et al, 2015 [2]. 
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Goats and sheep are the primary hosts for PPRV with few reports of disease outbreak in camels. Cattle, buffalo 
and pigs develop subclinical infection but are not capable of excreting the virus, and thus are not considered to 
be important in the epidemiology of the virus [2]. Infection of various wildlife species (mainly wild ungulates), has 




Disease severity depends on various factors: PPRV lineage, species, breed, immune status of animals. Various 
clinical manifestations of the disease have been described in the literature. Young animals are most severely 
affected, and goats are more severely affected than sheep. In its most severe form (peracute) animals are found 
dead. However, the disease can be mild or unapparent and circulate in a country causing little or no illness until 
susceptible goats are exposed.  Outbreaks tend to be associated with contact of immuno-naïve animals with 
animals from endemic areas. In addition to occurring in extensive-migratory populations, PPR can occur in 
village and urban settings though the number of animals is usually too small to maintain the virus in these 
situations.  
• Morbidity rate in susceptible populations can reach 90–100%  
• Mortality rates vary among susceptible animals but can reach 50–100% in more severe instances  
• Both morbidity and mortality rates are lower in endemic areas and in adult animals when compared to 
young animals. 
 
Three forms of clinical PPR are identified, namely: 
Acute form  
After an incubation period of 3-6 days, there is a sudden onset of fever, severe depression, loss of appetite, and 
clear nasal discharge. The serous nasal discharge becomes mucopurulent and resulting, at times, in a profuse 
catarrhal exudate which crusts over and occludes the nostrils causing respiratory distress. There is congestion of 
the conjunctiva, crusting on the medial canthus and sometimes profuse catarrhal conjunctivitis, causing eyelids 
to mat together with discharge. Tissues in the mouth can swell and ulcers form on the lower gums, dental pad, 
hard palate, cheeks and tongue. Necrotic stomatitis with halitosis is common. Erosions may resolve or coalesce. 
Severe watery, blood-stained diarrhoea develops in some animals, resulting in dehydration and weight loss. 
Pneumonia evidenced by coughing is common in later stages. Pregnant animals may abort. The prognosis is poor 
and death can occur within five to ten days of the onset of fever.   
Peracute form  
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• Frequent in goats, especially in situations of PPRV introductions into immuno-naïve flocks.  
• High fever, depression and death.  
• Higher mortality.  
 
Subacute form 
• Frequent in some areas because of local breed susceptibility, form commonly seen in experimentally 
infected animals. 
• Usually 10–15 days’ development with inconsistent signs; on or about 6th day post-infection, fever and 
serous nasal discharge is observed. 
• Fever falls with onset of diarrhoea and, if this is severe, may result in dehydration and prostration. 
 
Seasonal variations 
More frequent outbreaks are observed during the rainy season or the dry cold season. Also associated with 
seasonal periods of increased local trade in goats.  
 
Transmission 
Infected animals can transmit the virus to close in-contact susceptible animals through exhaled aerosol or 
clinical excretions (lacrimal, nasal, saliva, feces). Water, feed troughs, and bedding can also be contaminated 
with secretions and become additional sources of infection, however the virus does not survive for a long time 
outside the body of a host animal. The virus is temperature sensitive and readily inactivated in a dry 
environment.  Infected animals that recover from disease develop a lifelong protective immunity and no carrier 
state has been identified. However, virus can circulate in animals with mild disease, leading to disease 
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Table 1 summarizes the currently OIE recommended test methods available for the diagnosis of PPR and their 
purpose. 
 
Identification of the agent 
Agar gel immunodiffusion  
• Simple and inexpensive test that can be performed in any laboratory and even in the field  
• Standard PPR viral antigen is prepared from mesenteric or bronchial lymph nodes, spleen or lung  
• Results are obtained in one day, but the test is not sensitive enough to detect mild forms of PPR due to 
the low quantity of viral antigen that is excreted.  
Counter immunoelectrophoresis  
• Most rapid test for viral antigen detection  
Imunocapture enzyme-linked immunosorbent assay (icELISA) 
• There is one commercial kit, which is available from OIE PPR Reference laboratories. It is reliable where 
local technology cannot perform molecular techniques, although it is not as sensitive as PCR.  
• Using two monoclonal antibodies (MAb) raised to the N protein, allows a rapid identification of PPRV  
• Sandwich ELISA is widely used in India  
Nucleic acid recognition methods  
• Reverse transcription PCR (RT-PCR) techniques based on the amplification of parts of the N and F protein 
genes have been developed for the specific diagnosis of PPR.  
• Multiplex RT-PCR based on the amplification of fragments of N and M protein genes, has been reported. 
• A real time RT-PCR, or Quantitative RT-PCR (QRT-PCR) assay has been developed for the specific detection of 
PPRV. It can detect all four lineages of the virus; QRT-PCR is ten times more sensitive than the classical RT-
PCR.  
• LAMP techniques have also been described.   
 
Culture and isolation methods  
• Even when diagnosis has been carried out by rapid techniques, the virus should always be isolated from 
field samples in tissue cultures for further studies.  
• PPRV may be isolated in primary lamb kidney/ lung cells and some cell lines (Vero, B95a) 
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Table 1: Tests recommended by the OIE (OIE Terrestrial Manual of Diagnostic tests and vaccines for 


















of infection - 
surveillance 




Competitive ELISA ++ ++ - +++ +++ 
Virus neutralization +++ +++ - +++ +++ 
RT-PCR - - +++ - - 
Real Time RT-PCR (QRT-PCR) - - +++ - - 
Virus isolation in cell culture - - +++ - - 
Immunocapture ELISA - - +++ - - 
Agar gel immunodiffusion - - + - + 
Counter 
immunoelectrophoresis 
- - + _ _ 
Key: +++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability, or 
other factors severely limits its application; – = not appropriate for this purpose. 
Although not all of the tests listed as category +++ or ++ have undergone formal validation, their routine nature and the 




Virus neutralisation (the prescribed test for international trade)  
o Test is sensitive and specific but time-consuming  
Competitive enzyme-linked immunosorbent assay  
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A field test for PPRV has recently been developed at Pirbright Institute. This commercially available test is 
essentially a lateral flow device-formatted immunocapture test, and has been trialled in the field and found to 
be functional [3].  The test is based on the specificity and affinity of monoclonal antibody C77; this antibody 
recognizes the PPRV H protein, but not that of the related ruminant morbillivirus rinderpest.  
A Luciferase Immunoprecipitation System (LIPS) for the rapid detection of antibodies against PPRV in serum 
samples and for specific differentiation from antibodies against Rinderpest (RP) virus has been recently 
developed. PPR and RP serum samples were assayed by PPR-LIPS and two commercially available PPR cELISA 
tests. The PPR-LIPS showed high sensitivity and specificity for the samples tested and showed no cross reactivity 
with RPV unlike the commercial PPR cELISA tests which did cross react with RPV. Based on the results, PPR-LIPS 
is presented as a good candidate for the specific serosurveillance of PPR [4]. 
 
Differential diagnosis 
Peste des petits ruminants can be confused with other diseases such as rinderpest, bluetongue and contagious 
caprine pleuropneumonia, due to the similarity of these diseases in clinical signs.  Contagious ecthyma, FMD, 
heartwater, coccidiosis and mineral poisoning might also be considered. Diagnosis of the disease may also be 
complicated, as the result of secondary bacterial infections specifically caused by Mannheimia haemolytica.  
 
Immune response 
PPRV is highly lymphotropic and infection often leads to a profound immunosuppression that causes 
leucopoenia and reduced antibody responses. Immunosuppression by PPRV has been observed in both 
vaccinated and infected animals. Virulent strains of the virus cause marked immunosuppression, whereas 
vaccination only induces a transient leucopoenia with no significant effects on the immune response [2].  
Cellular and humoral immune responses are induced by infection but are also features of vaccination with the 
live attenuated vaccines that are available. The relative importance of humoral (antibody) and cell-mediated 
(cytotoxic T cell) responses in the recovery from infection with PPRV is not clear. Animals that recover from 
infection (including infection with the attenuated vaccine strains of PPRV) have high levels of circulating 
neutralising antibody as well as antigen-specific proliferating CD4+ T cells. The protective immune response of 
the host to PPRV infection is, in any event, obscured to some extent by the generalized immunosuppression 
common to infections with any of the morbilliviruses [1]. 
Maternal antibodies against the virus can be detected in young animals and remain able to neutralise virus for 
three to four months enabling a level of protection in newborn animals.  
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Sheep and goats vaccinated with an attenuated strain of PPR or that recover from PPR develop an active 
immunity. It is assumed that this protection is actually lifelong, as Rinderpest vaccine was observed to protect 
cattle (a naturally longer living species) for up to 10 years. For this reason, animals that have recovered from 
PPRV infection are assumed to be protected from the disease for life, although there are no published studies on 
attempts to re-infect animals that have recovered from the disease [1].  
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Since its first identification in the early 1940s in Côte d’Ivoire, PPR has steadily expanded its geographical 
distribution beyond its original endemic region in Western Africa. It occurs now in most African countries from 
North Africa to Tanzania.  A significant and dramatic geographical expansion of the disease has occurred over 
the last 15 years resulting in large parts of Central Asia, South Asia and East Asia now being endemic for PPR 
(Figures 2 & 3). It is present in the Arabian Peninsula, and nearly all Middle Eastern countries up to Turkey. 
Recent incursions into China (Tibet) and Morocco have caused serious disease outbreaks and disease has been 
reported to be moving southwards in East Africa.    
Currently around 70 countries have reported infection to the OIE or are suspected to be infected and another 50 
are considered at risk for PPR. Out of these infected countries, more than 60% are in Africa (including North 
Africa) the other infected countries being in Asia (South East Asia, China, South Asia and Central Asia/West 
Eurasia including Turkey) and the Middle East. 
There is an OIE established procedure to recognise countries free of PPR.   The latest official status as of May 
2015 can be seen in the following link: http://www.oie.int/en/animal-health-in-the-world/official-disease-
status/peste-des-petits-ruminants/list-of-ppr-free-members/.  Officially PPR free countries in Asia and Africa 
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Figure 3: Global PPR situation and occurrence of outbreaks between 2007-2014. (Source: Global strategy for 




There are two main sources, OIE and AU-IBAR (which includes only Africa), but data are not always similar.   
1st Source: OIE.   
 
Data of outbreaks reported to the World Animal Health Organization (OIE) are shown in Tables 2 and 3.  Data are 
not always reliable, as many countries do not seem to report, or to be reporting consistently over time.   
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
 
Similar information but presented in a different manner can be seen in Annex 1.   
 
Number of cases reported to the OIE by disease and by country: 
     -   No information,      +   Present but quantitative data not known,   ?  Disease suspected 
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Table 2: ASIA – PPR outbreaks notified to OIE from the Asian countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - + + + + + + + + - 
India 1,071 507 434 165 184 300 197 128 123 82 - 
Indonesia 0 0 - 0 0 0 0 0 0 - - 
Myanmar 0 0 0 0 0 0 0 0 0 0 - 
Nepal 51 174 320 >13 143 179 121 98 25 41 27 
Vietnam 0 0 0 0 0 0 0 0 0 0 0 




Table 3: AFRICA – PPR outbreaks notified to OIE from the Asian countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso + + + >12 2 5 7 11 1 17 2 
Ethiopia 41 115 54 67 75 113 85 103 116 44 - 
Ivory Coast 3 0 + >2 17 19 28 7 8 24 10 
Kenya 0 10 3 0 +? +? +? +? 4 29 8 
Madagascar 0 0 0 0 0 0 0 0 0 0 - 
Malawi 0 0 0 0 0 0 0 0 0 - - 
Mali 1 4 3 1 ? - 3 0 2 1 - 
Mozambique 0 0 0 0 0 0 0 0 0 0 - 
Rwanda - 0 0 ? 0 ? ? ? ? - - 
Senegal 9 5 7 28 25 6 9 5 9 4 1 
Peste des Petits Ruminants | Monograph 02 






South Africa 0 0 0 0 0 0 0 0 0 0 - 
Tanzania 0 0 0 1 > 2 >2 >2 >1 2 2 4 
Uganda 0 0 1 9 2 + + 1 + + - 
Zambia - 0 - - 0 +? 0 0 0 0 - 
Note: South Africa has OIE official freedom status.  
 
 
2nd Source: AU-IBAR. 
 
Number of outbreaks per year as reported to AU-IBAR and published in the Pan African Animal Resources 
Yearbook. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=). Table 4 
shows the number of PPR outbreaks reported to AU-IBAR.  Below the table, there are some relevant notes for 




Table 4:  Number of PPR outbreaks per year as reported to AU-IBAR and published in the Pan African 
Animal Resources YearBook.  Please see notes below the table for each year (NS= Not specified)    
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso    12 2 5 7 10 1 17  
Ethiopia 20  111 252 1 144 111 154 270 83  
Ivory Coast 2 2   17 17 28 11 2 24  
Kenya  NS 4     4  9  
Madagascar            
Malawi            
Mali    3   3  2 1  
Mozambique            
Rwanda            
Senegal 4 6 13 31 32 2 5 6 9 4  
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South Africa            
Tanzania      NS 2 1 2 2  
Uganda  NS 5 2   4 1 8 2  




First reports of PPR in Kenya were in March 2006, in North Turkana District.  In Uganda, the PPR outbreak 
started in 2006. The disease has been showing geographical advances towards the southern and northern 
regions of Africa with Tanzania (2008) and Zambia (2010) in the south and Algeria (2011). Egypt became infected 
in 2012. 
 
Prevalence data by country 
o Sources: PubMed, and internet engine searches (English and French when applicable).   
o Efforts have been made to include the year of the study, and not the year of the publication. If they are 
known to be different, the year of publication is included in the reference.  
o Note that not all papers have been read in full. In many cases, only the abstracts have been read. Critical 
evaluation of the papers for inclusion has not been conducted.  If a review paper included some 








% positive Reference 
2014 Upazila Veterinary Hospital, 
Thakurganon 




Chittagong District Goats 5,485 8.99 Parvez et al, 2014 
2012 Upazila Veterinay Hospital, 
Cox’s Bazar.  
Goats 182 47 Islam et al, 2014 
2010-
2011 
Rajshahi District Goats 627 20.57 Sarker and Islam, 
2011 
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2010 Upzilla Veterinary Hospital, 
Mohammadpur, Magura 
Goats 209 5.3 Karim et al, 2014 
2010 Sujanagar, Sathia and Bera, 
Pabna district 
Goats 6,408 2.18 Rahman et al, 2011 
2010 Mirzaganj upazila, Patuakhali 
District 
Goats 183 50.27 Islam et al, 2012 
2008 Upazila Veterinary Hospital, 
Kushtia Sadar 






Year Area Species of 
animal 
No.  samples tested % positive Reference 
2013-
2014 
North-East India Goats 391 17.90 Balamurugan et al, 
2014 
2012 Gujarat Sheep, goats, 
cattle, buffaloes 
and camels 
Sheep: 355, Goats: 141, 
Cattle: 80, Buffaloes: 







Pradip et al, 2012 

































Sheep and goats 
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Seroprevalence of peste des petits ruminants in sheep and goats by state for the 2003–2009 period. Source: 




The disease has never been reported in Indonesia.  Source: Sendow, 2014.  
 
Nepal  
No information on the prevalence of PPR in Nepal was found. 
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2006-
2008? 





o The disease has never been reported in Madagascar, Malawi, Mozambique and South Africa.  




Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 








(Details in table below) 





Prevalence anti-PPR antibodies per department in Soum Province. Source: Sow et al, 2008 
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 








Molla and Delil, 
2015 
2012 Awash Fentale Sheep and 
goats 
 Before outbreak: 7.3 
After outbreak: 42.6 
Delil et al, 2012 
2006-
2007 




1,239 1.70 Faris et al, 2012 
2001 Afar, Borena, East 
Shewa, Gambela, Jijiga 








Abraham et al, 
2005 













Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
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Year Area Species of 
animal 
No. of samples tested % positive Reference 




Grant’s gazelle: 30 






Grant’s gazelle: 66 





Mahapatra et al, 
2015 










2011 Mtwara region Goats and 
sheep 
216 31 Muse et al, 2012 






Lembo et al, 2013 
2009 Ngorongoro, 
Monduli, Longido, 








Swai et al, 2009 






Mbyuzi et al, 2014 
2008-
2009 
12 districts Arusha, 
Kilimanjaro, 







Kivaria et al, 2013 
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2012 Makindye, Rubaga, 
Nakawa, Kawempe, 
Wakiso, Greater and 
Central Kampala 





















There was an outbreak reported in May 2015. The previous outbreak was when the disease was first reported in 
2010. Source: Pro-med. There are no reports available on prevalence. 
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Economic and Social Impacts at Global 







FAO and OIE during 2015 unveiled the Global strategy for the control and eradication of PPR [5][6], in which the 
organizations noted that PPR is present in around 70 countries in Africa, the Middle East and Asia, threatening 
more than 1.7 billion of the total global population of 2.1 billion sheep and goats, as well as the livelihoods, food 
security and nutrition of more than 330 million people in these regions – mainly poor farming communities that 
rely solely on small ruminant production for their survival. Another 50 countries are at risk of incursions of the 
disease from neighbouring areas, threatening an additional 167 million sheep and goats.  
Morbidity, mortality and production 
In the worst situations, PPR-related morbidity is 100%, with up to 90% mortality. In areas where the disease is 
endemic, the mortality rate may be lower; yet the disease has an insidious impact, hampering the development 
of lambs and kids and compromising the immune defense of adult animals against other diseases. The rates 
depend on methodology used in data collection, species and farming systems, as exemplified by Kimani et al, 
2015, Socio-economics of PPR presentation at FAO and OIE Conference for the control and eradication of PPR in 
Abidjan:  
• In endemic countries morbidity rates range from 6.2 to 65% in Somalia and 48.4 to 56.6% in Cote 
d’Ivoire 
• During epidemics these rates rise to between 86 to 100% (reported in Kenya, Ethiopia and Eritrea) 
• Mortality rates also vary with reports - 0-97% in Cote d’Ivoire; 69 to 74% in Tanzania; 33 to 90% in 
Kenya, Ethiopia and Eritrea 
• Two studies from India indicate that while the mortality rate was relatively low per animal affected, the 
overall losses were high even when the animal recovered 
As for effects on production, Kimani et al, also mentioned:  
• In Tanzania it was estimated that 330,910 kids/lambs were not born due to abortions. 
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• In Kenya and Tanzania 10% of households lost their entire herd or flock 
• It was estimated that in Kenya, Tanzania and Somalia milk production losses were in the region of 2 
million litres 
Overall, PPR is a limiting factor to the development of healthy and thriving flocks and herds. 
 
Economic impact 
Rushton et al, present in Annex 1 of the PPR Global strategy already mentioned, the details of the socio-
economic impact of PPR.   They estimate the direct annual losses due to PPR between USD 1.2 and 1.7 billion. 
The estimated current expenditure on PPR vaccination ranges between USD 270 and 380 million. The annual 
impact of PPR alone may be valued at between USD 1.45 and 2.1 billion per year.  This was estimated using the 
assumptions that two thirds of the animals affected would die, and that would mean a loss of USD 35 per animal 
that dies, and USD 3.50 per animal affected that recovers.  The cost of vaccination was estimated at USD 0.80 
per dose delivered (cost of the dose, and the time of the people involved). A sensitivity analysis included the 
value of a dead animal at USD 50, and USD 5 for an animal that recovered. Approximately a third of the global 




Figure 4: Impact of PPR in USD millions. Source: Global strategy for the control and eradication of 
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Economic rationale for global control 
The estimated maximum undiscounted costs for a fifteen-year global PPR strategy is between US$7.6 and 
US$ 9.1 billion with the first five years costing between US$ 2.5 and 3.1 billion (Rushton et al, 2015. Annex 5 
– Costing of the PPR global control and eradication strategy, in FAO & OIE Global strategy for the control 
and eradication of PPR). The lower range is 16.5% less and would be expected as a consequence of a rapid 
decrease in PPR incidence in countries employing an effective vaccination strategy. In all scenarios tested 
there are significant vaccination campaigns that could well be reduced with strong targeting of at risk 
populations through carefully epidemiological and economic analysis. These costs have also given a realistic 
figure on vaccine dose costs and an amount to cover the delivery costs in different scenarios. These costs 
need to be placed into the perspective of the numbers of animals that are being protected by the measures 
proposed – nearly a billion sheep and a billion goats. A rough estimate of the average cost per shoat per 
year would mean an investment of between US$ 0.27 and 0.32. 
The current annual impact alone of PPR is between US$1.45 to 2.1 billion per year, and with a successful 
eradication program this impact would be reduced to zero. A control and eradication program at an 
estimated cost of USD 2.5 billion (undiscounted costs) over an initial 5-year period (i.e. approximately USD 
0.5 billion per year) appears small in comparison. A reduction of 42% in the impact of PPR would justify the 
annual expenditure alone. It is important to recognize that without the strategy anything between US$ 4.0 
and 5.5 billion would be spent over a fifteen-year period on poorly targeted vaccination campaigns that is 
unlikely to lead to eradication. In summary the global spending in the current structures will cost between 
US0.14 to 0.20 per sheep or goat year which will not result in eradication. 
 
Country examples (focus on countries of interest) 
1. India 
o Thombare and Sinha in 2009, reported on a cross-sectional sample survey conducted across six villages severely 
affected by PPR disease in the Pune district of Maharastra, during 2005-6.  The incidence and mortality rate were 
found slightly higher in sheep than goats. The total losses due to disease ranged from Rs 918 in sheep (USD 19 
using exchange rate of June 2009) to Rs 945 in goats (USD 19.4). Reduction in the market value of animals was 
recorded as the major loss component as appearance of the animal changes drastically after the illness, costing 
Rs. 404 (USD 8.3 - 44 %) in sheep and Rs 408 (43%) in goat, and this was followed by losses in production yield. 
Expenditure on medicine and infertility was found to cause more than 80 per cent of the total cost, followed by 
veterinary and labour services. The authors suggested that timely vaccination could be the best and low-cost 
preventive measure to control such deadly disease outbreaks. 
 
o Awase et al, 2013, using primary data from villages of Indore division of Madhya Pradesh, calculated that the 
overall incidence rate in goat of Indore division was 8.7 % and mortality rate 3.2 %. The total economic losses 
due to PPR was found to be Rs.523 (approx. USD 8.76) per affected animal. The production loss due to reduced 
body weight comprised the maximum proportion and it was about Rs.278 (USD 4.6) accounted for 53.2 per cent 
of total loss. The economic loss in market price of goat due to poor physical appearance was Rs. 137 (USD 2.3) 
was the next most important, comprising nearly 26 per cent. The treatment cost which include medicine cost, 
registration or consultancy fee, miscellaneous expenses was Rs.108 (USD 1.8) per goat. 
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o Singh et al 2015, used 2 methodologies for their calculations. Based on data reported by the Government of 
India between 2008-2012, the study showed average annual economic loss of Rs. 167.83 lacs (approx. USD 
345,000), of which Rs. 125.67 lacs (USD 258,000) and Rs. 42.16 lacs (USD 86,000) respectively are due to the 
incidence of the disease in goats and sheep.  Morbidity losses constituted the greater share of the total loss in 
both goats and sheep (56.99% and 61.34%, respectively). Among different components of morbidity loss, direct 
body weight loss was the most significant in both goats and sheep. Based on cases and deaths as reported in 
sample survey studies, the estimated annual economic loss due to PPR in goats and sheep is Rs. 8895.12 crores 
(approx. USD 1,298 million), of which Rs. 5477.48 (approx. USD 799 million) and Rs. 3417.64 crores (approx. USD 
498 millions) respectively are due to the disease in goats and sheep. The authors said that the calculations using 




o Kihu et al. 2015, observed that PPR was a major economic disease affecting the pastoral herders in Kenya, with 
outbreaks in Turkana County having devastating effects on the Turkana livelihoods. The study estimated the 
direct economic losses occasioned by outbreaks of PPR based on perceived loss of benefits experienced by the 
Turkana people. They estimated the losses due to PPR at US$ 19.1 million and that mortality due to PPR 
constituted the greatest economic loss valued at US$ 16.8 million being 88% of the total losses. Other losses due 
to lost milk and weight loss constituted approximately 12% of the total losses. They concluded that PPR has 
serious economic impacts on pastoral livelihoods, and that previous estimation of PPR losses in Kenya was 
grossly undervalued.  
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Currently, there are no medications available to treat the disease, but supportive treatment may decrease 
mortality.  Antibiotics may help with secondary pulmonary infections.  
Effective and rapid control of PPR is foreseeable using cheap antiviral compounds – they could be used to limit 
the clinical impact of PPR quickly in emergency situations while immunity by vaccination develops, in the context 
of introduction into a new area or re-emergence in endemic areas. Antivirals based on synthetic short 
interfering RNAs (siRNAs), a new class of molecules with a significant potential for therapeutic applications could 
be good candidates since they can be delivered in viral vectors and biologically synthesised in the treated 
animals. Servan de Almeida et al [7], described that nucleocapsid genes of PPRV and RPV can be targeted 
efficiently by siRNAs, resulting in a >80 % reduction in virus replication.  However, along with the development 
of efficient RNAi-based therapeutics comes the risk of emergence of resistant viruses. Holz et al 2012 [8], 
challenged the in vitro propensity of PPRV, a stable RNA virus, to escape the inhibition conferred by single or 
multiple siRNAs against conserved regions of the N gene. Except with the combination of three different siRNAs, 
the virus systematically escaped RNAi after 3 to 20 consecutive passages. The genetic modifications involved 
consisted of single or multiple point nucleotide mutations and a deletion of a stretch of six nucleotides, 
illustrating that this virus has an unusual genomic malleability and that the generation of escape mutants with 




When the disease appears in a previously unaffected area, the standard disease control measures consisting of 
quarantine, movement control, sanitary slaughter, and cleaning and disinfection are applied. The virus is 
susceptible to most disinfectants.  Vaccines are used where the disease is established and it provides good 
immunity. For more details on the vaccine, see Section 6.  
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Epidemic outbreak situations: when the disease appears in previously PPR-free zones or countries.  
• Rapid identification, humane slaughter and disposal of affected animals and their contacts; carcasses burned 
or buried  
• Strict quarantine and control of animal movements  
• Effective cleaning and disinfection of contaminated areas of all premises with lipid solvent solutions of high 
or low pH and disinfectants; includes physical perimeters, equipment and clothing  
• Careful consideration to use of vaccine; strategic ring vaccination and/or vaccination of high-risk populations  
• Monitoring of wild and captive animals  
 
Endemic outbreak situations: when is continually circulating.  
• Most commonly employed control mechanism is vaccination  
• Sheep and goats vaccinated with an attenuated strain of PPR or that recover from PPR develop an active 
life-long immunity against the disease  
• Monitoring of wild and captive animals; especially avoiding contact with sheep and goats  
• Exposed or infected animals should be slaughtered and the carcases should be burned with deep burial.  
 
Options and strategies for control programs at national, sub-national, regional and global level 
A number of countries and regions have embarked on the control of PPR, often with assistance and/or advice 
from FAO and OIE. However, many of these national programs are inadequately resourced and poorly 
coordinated and could benefit significantly from a concerted, well-funded effort to make any impact. 
Since 2011, FAO and OIE have supported the formulation of PPR control and eradication strategies for regions 
covered by the South Asian Association for Regional Cooperation (SAARC), Southern African Development 
Community (SADC), Intergovernmental Authority on Development (IGAD) and the African Union’s Inter-African 
Bureau for Animal Resources (AU-IBAR).  
An example of the control measures taken by some African countries to control PPR in 2008, can be seen in 
Figure 5. Number slaughtered means the number of animals killed for salvaging products partly or entirely for 
consumption or other use as part of a disease control strategy. Number destroyed refers to the number of 
animals killed and buried or burned as a means of disease control. 
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Figure 5: Control measures undertaken by affected countries during 2008 and some related quantitative 
data.  Source: AU-IBAR Pan African Animal Health Yearbook, 2008. 
 
Progressive control and eradication of PPR 
 
In response to calls from member countries, FAO and OIE have taken the lead in developing a Global Strategy for 
the control and eradication of PPR [5][6] – See Figure 6. They believe PPR can be eradicated within 15 years, provided 
it is adequately resourced and well-coordinated at all levels, with the political commitment and participation of 
key partners.  This is less than half the time it took to eradicate rinderpest.  In addition, other high impact infectious 
diseases of small ruminants could be controlled, at a relatively small incremental cost, if linked to PPR control and 
eradication. These may include sheep and goat pox, brucellosis and contagious caprine pleuropneumonia.  
 
The Global Strategy for the control and eradication of PPR has 3 integrated components: 
1- PPR control and eradication 
2- Strengthening veterinary services  
3- Prevention and control of other major diseases of small ruminants 
 
 
An overview of the objectives, outputs and other aspects of the strategy can be seen in Table 5.  
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Table 5: Overview of the FAO/OIE Global Strategy for the control and eradication of PPR. Source: FAO/OIE 
Global control and eradication of PPR – investing in veterinary systems, food security and poverty 




> Progressively reduce the incidence and spread of PPR and ultimately eradicate PPR 




> PPR eradicated globally 
> Improved control of other important diseases of small ruminants (e.g. goat and sheep pox, brucellosis 
and foot and mouth disease) 
> Enhanced capacity of Veterinary Services to control PPR and other livestock diseases 





> Improved contribution of the small ruminant sector to food security and nutrition, food safety, public 
health and national economic development 
> Significant reduction in poverty through enhanced livelihoods of over 330 million poor livestock 




> Large-scale, vaccination in endemic countries with existing, live, attenuated, efficacious vaccines and 
establishment of regional vaccine banks  
> Surveillance and post-vaccination evaluation and monitoring using available diagnostic tests ensuring 
that vaccination results in increased flock immunity, reduced disease incidence and eventually reduced 
virus circulation and elimination  
> Evaluation of Veterinary Services capabilities and investment needs through the use of the 




The strategy is presented at 3 different levels: national, regional and global.  
 
At national level, the strategic approach is based on 4 stages, corresponding to a combination of decreasing levels 
of epidemiological risk and increasing levels of prevention and control capabilities, as seen in Figure 7. In Stage 1 
the epidemiological situation is being assessed, and in Stage 4, the country can provide evidence that there is no 
virus circulating either at zonal or national level.  
 
At regional level, the focus is on regional coordination and harmonisation of national strategies and activities.  
Regional Economic Communities and other relevant regional organisations such as the African Union- Inter African 
Bureau for Animal Resources (AU-IBAR) in Africa are expected to play an important role.  
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At global level, will create a new Global Secretariat for the implementation of the Global PPR control and 





Figure 7: The progressive step-wise approach for the prevention and control of PPR. Source: Global strategy 
for the control and eradication of PPR, 2015. FAO & OIE [5]. 
 
Regional Roadmaps 
The Global strategy has developed 9 regional roadmaps, which provide countries with a common long-term 
vision and create incentives for them to develop and embark on national risk reduction strategies with similar 
progress objectives, milestones and timelines (see Figure 8). 
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Figure 8: Regional Roadmaps for PPR control and eradication.  Source: Global strategy for the control and 
eradication of PPR, 2015. FAO & OIE [5]. 
 
Regional situations for the areas that include the focus countries: 
(as described in the 2015 Global Strategy for the control and eradication of PPR) 
 
South Asia 
In South Asia, a regional roadmap was formulated in 2011 by the SAARC member countries and it will be 
reviewed every two years. With the exception of Sri Lanka, all SAARC countries have reported PPR infection; 
however, the disease was reported only once in Maldives and Bhutan. Each SAARC country has a national 
laboratory suitable for PPR diagnosis and the Bangladesh national laboratory currently serves as the regional 
laboratory. Surveillance is ongoing as well as vaccination campaigns in high-risk-identified areas. Bangladesh, 
India and Nepal are producing PPR vaccine; however, there is an urgent need to improve the quality and 
quantity of these vaccines to meet national and regional requirements. At a regional meeting held in December 
2013 several challenges were identified, including the lack socioeconomic impact assessment across the value 
chain, the need to develop a strategic plan and ensure a budget for its implementation and to enhance technical 
expertise and skills. Agreement was also reached on the need to raise awareness among farmers, to formulate 
or revise and enforce regulations regarding animal movements, to harmonize laboratory diagnostic tests in the 
region and to deliver quality assured vaccines. Some countries benefit from strong FAO technical support, such 
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as Afghanistan and Pakistan where disease surveillance, laboratory diagnostic capacities, vaccine production and 
vaccination campaigns are being strengthened. 
 
Eastern Africa 
In Eastern Africa all countries are infected and a regional strategy has been developed aimed at developing or 
improving a series of activities, including surveillance, diagnostic procedures, vaccination and awareness 
campaigns. Currently, prevention and control measures for PPR as well as other diseases are based on 
vaccination campaigns conducted mostly in response to disease outbreaks and hence are focused around the 
outbreak area (i.e. ring vaccination). Nevertheless, mass PPR vaccination campaigns were conducted in Kenya in 
2008/2009 and Somalia in 2012/2013, and there are plans for conducting them in Ethiopia. The Nigeria 75/1 
strain (produced in Ethiopia, Kenya and Sudan) was used in these vaccination campaigns. The use of a 
thermotolerant vaccine would be an important improvement for vaccination efficacy. 
 
Southern Africa 
Most countries in Southern Africa are currently free from PPR but the SADC member countries, after the 
introduction of PPR in a few countries, developed in 2010 a regional PPR control strategy.  
Link: http://www.sadc.int/files/7413/5542/4349/PPR_Strategey.pdf  
The main objectives of this strategy are as follows:  
1. to immediately contain/control PPRV circulating in Angola, Democratic Republic of the Congo and 
Tanzania, 
2. to prevent the disease from spreading to Malawi, Mozambique and Zambia, 
3. to propose a methodology for the long-term eradication of PPR from the SADC region. 
Currently, only Botswana produces PPR vaccines in the SADC region. South Africa has an OIE recognized official 
PPR free status. Support is being given by the FAO and IAEA to enhance laboratory diagnosis and vaccine 
production capabilities, improve disease surveillance, undertake socio-economic studies on PPR impact, and 
strengthen coordination/harmonization of PPR prevention and control in the region. 
 
Central Africa and West Africa 
All countries in Central and West Africa are infected. Regional meetings and conferences have already addressed 
the PPR issue (e.g. Conferences of the OIE Regional Commission for Africa) and FAO has implemented several 
national projects supporting activities in laboratory diagnostic (together with IAEA), surveillance and other field 
operations or vaccine production (together with AU-PANVAC), formulation of national strategic plans, etc. 
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Vaccination campaigns are undertaken in endemic and at-risk areas but the achievements are not always 
optimal.  
A pilot field project funded by the Bill & Melinda Gates Foundation was carried out by the OIE in Ghana and 
Burkina Faso to identify the major constraints that may hamper the successful implementation of vaccination 
programs. Various productions systems and vaccine delivery systems (public and private) were considered in the 
study and several evaluation methods were tested. Logistical issues and communication directed at owners and 
vaccinators were among the principle factors that could determine positive achievements or failures. This field 
component was combined with two other components, namely the improvement of the quality of PPR vaccines 
produced in Africa, implemented by AU-PANCVAC, and the establishment of a vaccine bank. Currently, Niger, 
Nigeria, Mali and Senegal are PPR vaccine producers. At the regional level, a number of limiting factors have 
been recognized, such as the efficacy of the delivery systems, particularly in the case of small-scale production 
systems or those in remote and insecure areas, and the vaccine cold chain. In Central and West Africa, the 
relevant RECs (ECOWAS, CEMAC, CEBEVIRHA, WAEMU, etc.) and other regional organizations continue to 
strengthen their political commitment as well as their financial and technical support together with their 




Disease situation and government policies by country 
Tables 6 and 7 below have been completed with the information received from the questionnaires sent to the 
DG and DVS for PPR.   
Table 6 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation.  Table 7 refers to the vaccination situation. 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely 
dissemination of information to those who need to know so that action can be taken.  
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a 
country for the purpose of controlling a vector, pathogen or disease by specific measures applied 
throughout that country, or within a zone or compartment of that country. 
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Table 6: Official status, official programs and treatment for PPR in the countries of interest.  
Information provided by the questionnaire sent to the DG/DVS as part of this monograph. Replies were not 




















Bangladesh Yes Yes, passive Yes (limited to some 
districts) 
Yes Yes 
Myanmar (Burma) Yes Yes, passive No No No 
Nepal Yes Yes, active Yes N/A N/A 
Vietnam* No No No - - 
AFRICA 
Burkina Faso      
Côte d'Ivoire (Ivory 
Coast) 
Yes Yes, passive but active if 
outbreak 
Yes No - 
Kenya Yes Yes, passive Control strategy in 
place 
No No 
Malawi Yes Yes, active and passive Yes N/A N/A 
Mali Yes Yes, passive Yes No No 
Rwanda Yes Yes, active and passive Yes No No 
Tanzania Yes Yes, active and passive Yes No No 
Uganda Yes Yes Yes Yes Yes 
Zambia Yes Yes, active Yes Yes No 
* The reply from Vietnam is surprising but might have been a mistake with the line below (sheep and goat pox) in the 
questionnaire. 
Peste des Petits Ruminants | Monograph 02 






Table 7: Vaccination for PPR in the countries of interest. Information provided by the questionnaire sent to 
the DG/DVS as part of this monograph. Replies were not received from India, Indonesia, Burkina Faso, 






















Bangladesh No Combination. 
Government subsidy, 




Goat and sheep 
Myanmar (Burma) No - - - 
Nepal No Government Official Sheep and goats 
Vietnam No - - - 
AFRICA 
Côte d'Ivoire (Ivory 
Coast)  
- Government / Farmer Government Sheep and goats 
Kenya As per strategy Combination Both Sheep and goats 
Malawi No N/A N/A N/A 
Mali Yes Combination Official Sheep and goats 
Rwanda Yes Government Official Goats and sheep 
Tanzania  Yes Combination Both Goats and sheep 
Uganda No Government Both Goats and sheep 
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Zambia* Yes Government Official Goats 
*I t is surprising that Zambia vaccinates for PPR, as it only had a couple of outbreaks. Might be in the risk 
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In the absence of homologous vaccines, and since Rinderpest virus (RPV) and PPRV share a high homoloogy at 
the nucleotide level, and a high degree of antingenic cross-reactivity, the attenuated tissue culture RPV vaccine 
was used for a long time as an heterologous vaccine, to protect small ruminants against PPR.  
At the end of 1980s, the first homologus vaccine was developed when a PPRV strain was successfully attenuated 
by Diallo and colleagues [9]. It was based on a PPRV isolated by from Nigerian goats that had died from PPRV 
infection in 1975 (Nigeria 75/1) and was adapted to Vero cells at 37°C . The isolate was proved to be a powerful 
substitute for the heterologous vaccines.  
In 1998, OIE endorsed the use of homologous vaccines in countries that had decided to follow the ‘OIE pathway’ 
for epidemiological surveillance for rinderpest, and after the global RP eradication, the OIE made clear that 
heterologous vaccines should not be used. 
 
Live attenuated vaccines 
The only currently available PPR vaccines, are cell culture-attenuated strains of natural PPRV. The first vaccine, 
the Nigeria 75/1 has been used extensively in Africa and the Middle East, but other strains have also been 
developed.  Currently, there are six available PPR vaccine strains: 
1. Nigeria 75/1 (Nigeria, lineage II; isolate of goat origin)  
2. Sungri 96 (India, lineage IV; isolate of goat origin) 
3. Arasur 87 (India, lineage IV; isolate of sheep origin) 
4. Coimbatore 97 (India, lineage IV; isolate of goat origin) 
5. Titu (Bangladesh, lineage IV; isolate of goat origin)  
6. 45G37/35‐K PPR Vaccine (Kazakhstan, lineage IV?). 
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DOSE: Studies with the Nigeria 75/1 calculated the effective dose to be 100.8 TCID50/animal; however, a dose of 
103 TCID50/animal also proved to be safe [10]. The OIE says that normally, the minimum immunising dose is 100x 
the lowest dose of vaccine virus able to induce 50% immunising response, and for Nigeria 75/1, the minimum 
titre is 102.5 TCID50.  
ONSET OF IMMUNITY: After vaccination with standard PPRV vaccines, antibodies can be detected clearly at 14 
days post vaccination. Full protection is achieved from standard doses of vaccine at three weeks post 
vaccination. Anti-PPRV antibodies elicited by the Nigeria 75/1 vaccine are highest during 30 to 45 days post-
vaccination [11].  There are no studies investigating if protection can be achieved earlier with higher doses of 
vaccine. 
EFFICACY and DURATION OF IMMUNITY: The vaccine in the field was shown to be protective against wild-type 
PPRV virus. With the Nigeria 75/1 prescribed vaccine dose of 102.5 TCID50, a single injection confers a long lasting 
immunity (at least 3 years) against all known PPRV genotypes (to date, a single serotype has been described), in 
all parts of the world in which it has so far been used (from Africa through to China).   
SAFETY: A number of field trials were conducted on more than 98,000 sheep and goats in the period 1989–1996, 
demonstrating that the Nigeria 75/1 vaccine could not cause unwanted side effects such as abortion in pregnant 
animals, and vaccinated animals were unable to transmit the challenge virus to others [12]. Pregnant animals 
remained safe and were able to pass passive immunity to their offspring, which remained protected for 3–5 
months.  Reversion to virulence experiments were done with the Nigeria 75/1 strain. No reversion was observed 
after three back passages in animals. Importantly, after more than 25 years of use in field situations, including 
vaccination in PPR outbreaks, no incident has been noticed [1].  
DIFFERENT STRAINS:  
According to Sen et al, 2010 [12], since lineage IV is mostly restricted to Asian countries, the use of Nigeria 75/1 
vaccine in Asian countries may increase the likelihood of mixing up of lineages and the development of mutants 
with high virulence. Thus, it is imperative to consider using the lineage-specific vaccine available for use in Asian 
countries. To this effect, some vaccines using lineage IV virus were developed in India (Sungri 96, Coimbatore 97 
and Arasur 87).  They all have been proven to be effective in terms of protection, and have been produced by 
passages in Vero cells.  The Sungri 96 was the earliest vaccine strain developed at the Rinderpest Laboratory, 
Indian Veterinary Research Institute (IVRI) from an isolate from Sungri, in Himachal Pradesh. The genome 
sequence of Sungri 96 showed 96 to 99 % identity with the Asian isolates and 89 to 92 % identity with the 
African isolates. The Sungri 96 vaccine has been tested extensively in the laboratory and field to demonstrate 
that it was safe and efficacious in sheep and goats. It has also been demonstrated that it can provide sterile 
immunity for at least 6 years and therefore is used throughout India to vaccinate sheep and goats with great 
efficacy [12].  
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The Arasur 87 and Coimbatore 97 were originally isolated from southern part of India. Although the Arasur 87 is 
closely related to the Sungri 96 in antigenicity, both can easily be differentiated based on the pattern of 
cytopathic effect and the degree of neutralization using specific monoclonal antibodies [13].  
In the study done by Saravanan et al., 2010 (14)[14], the potency of 4 of these vaccines was tested in accordance 
with OIE guidelines. The vaccines tested were the Sungri 96 produced by IVRI, Arasur 87 produced by TANUVAS 
(Tamil Nadu Vet Sciences University), Arasur 87 produced by IAH&VB (Institute of Animal Health and Veterinary 
Biologicals, Bangalore) and Coimbatore 97 produced by TANUVAS. There were 6 goats vaccinated with each 
vaccine, and 2-4 sheep vaccinated. The results showed that Sungri 96 and Arasur 87 (TANUVAS) protected sheep 
and goats from clinical signs, all swabs collected were negative for the virus and all animals were ELISA positive. 
Animals vaccinated with Coimbatore 97 were protected from clinical signs and all swabs were negative, but 
there was not 100% seroconversion.  The vaccine Arasur 87 from IAH&VB did not protect goats from clinical 
signs (there was only one sheep protected, as the other one died of unrelated causes, so due to the small 
numbers it is not possible to conclude on sheep protection), the swabs were positive for PPRV, and animals did 
not show sero-conversion.  The differences between the 2 strains of Arasur 87 were not ascertained.  
No information has been found on the Titu strain from Bangladesh, besides their mention in several papers with 
no details. 
As for the 45G37/35‐K information has been found in Russian, and the below information has been obtained 
with Google translate; therefore caution is needed with its interpretation.  The original link for the information 
is: http://ej.kubagro.ru/2012/09/pdf/31.pdf.  In 1990, in the former USSR, a 45G37 vaccine was obtained using 
primary cell cultures of kidneys and testicles of sheep and goats, and later passaged in Saiga kidney cells at 
VNIIVViM (State Science Institution National Research Institute of Veterinary Virology and Microbiology of 
Russian Academy of Agricultural Sciences).  High immune responses were induced 14-21 hours after vaccination.   
It is possible that the original references is: A study of cultural properties of the vaccine strain 45G37 / 35-K virus 
peste des petits ruminants / IP Mikhalkin , TF Gorshkov, LI Anisimova et al. // Scientific basis for the production 
of veterinary biologicals. - Shchelkovo, 2005, pp 163-166.  
http://www.dissercat.com/content/optimizatsiya-uslovii-kultivirovaniya-virusa-chumy-melkikh-zhvachnykh-
dlya-polucheniya-diagn#ixzz40yOGsBUL 
DIVA: The available PPR vaccines do not support the DIVA principle. The only vaccines in use are attenuated 
forms of the virus, and there is no consistent difference in antibody responses to these viruses and wild-type 
forms of the virus.  
THERMOTOLERANCE: Although all the mentioned vaccines are highly efficacious, they are susceptible to 
thermodegradation, thereby requiring transportation at 2 to 8 °C and be stored at −20 °C.  There are many 
publications and attempts to increase thermotolerance, from chemical stabilizers, to the use of thermo adapted 
strains.  Many of them claim good results but the only one that has been independently validated to be used in a 
commercial process, and so far has commercially been used in Africa is the Xerovac technology as described by 
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Worrall et al, 2001 [15] in which viruses are dehydrated in vitro, within 18 h, in an excipient containing trehalose. 
With this process, the vaccine resisted 45°C for a period of 14 days with minimal loss of potency. However, the 
Xerovac is limited by technological conditions, and some African laboratories have ceased using it. 
 
Chemical stabilizers 
Different stabilizers, such as lactalbumin hydrolysate-sucrose (LS), Weybridge medium (WBM), lactalbumin 
hydrolysate-mannitol (LM), buffered gelatine-sorbitol (BUGS) and trehalose dihydrate (TD), have been evaluated 
to prepare lyophilized PPR vaccines. The OIE recommends the use of WBM as a chemical stabilizer for PPR 
lyophilized vaccines, but vaccines are still susceptible to thermal degradation in the absence of a cold-chain 
system. Asim et al. 2008 [16], reported that PPR vaccine lyophilized with the WBM was more stable and 
maintained the virus titre longer than with two other stabilizers. In contrast, another study conducted by Sarkar 
et al 2003 [17], revealed that the PPR vaccine lyophilized with either LS or TD is more stable than with both WBM 
and BUGS, having an expiry period of at least 45 days at 4 °C, 15– 19 days at 25 °C and 1–2 days at 37 °C. 
However, at 45 °C, BUGS had a marginal superiority, although lasted for few hours, followed by TD and LS with 
respect to shelf-life, LS and TD with respect to half-life. See Table 8.  
Riyesh et al. 2011 [18] assessed two stabilisers, LS and stabilizer E (trehalose, CaCl2 and MgCl2) for their stability at 
different temperatures, using Thermo adapted strains developed in India. The results showed that both the 
stabilizers performed equally well with regard to shelf-life and half-life, and showed an expiry period of 24-26 
days at 25°C, 7-8 days at 37°C and 3-4 days at 40°C. The LS was superior at 42 °C with a shelf-life of 44 h, 
whereas in stabilizer E, a 40 h shelf-life with a comparable half-life was observed.  At 45 °C, the half-life in 
stabilizer E was better than in LS and lasted for 1 day.  See Table 8. The vaccine in stabilizer E fared better in 1 
mol/L MgSO4 diluent for 30 h at 4 °C and for 24 h at 25 °C as well as at 37 °C. The same vaccine with the LS, 1 
mol/L MgSO4 was found suitable for 48 h at 4 °C but at 25 °C and 37 °C, the stability lasted for 24–30 h. 
A publication from Silva et al 2011 [19] reported good results using a Tris/Trehalose formulation, compared to 
WBM. Data in Table 8 shows the data presented in the results section of the paper (which seems different from 
the abstract).  Later on, this formulation was evaluated with good results by the same authors, with the vaccine 
produced at the National Veterinary Institute in Ethiopia, especially at 37 and 45°C.  It is not clear the shelf and 
half-life obtained that time [20]. 
Mariner et al, presented data on thermostability of various formulations of PPR vaccines using lactalbumen 
hydrolysate (LAH) 2.5% with 5% sucrose, or with 5% trehalose. They also used 5% trehalose alone and Xerovac. 
The results have not been published in a peer-reviewed journal, and are only available in the Proceedings of the 
Global PPR Alliance Meeting, April 2013, pages 29-30. The results are difficult to interpret, there is no clarity on 
results and groups, and there seem to be inconsistencies between statements in the abstract and the body of 
the poster presentation.  It is difficult to judge these formulations without the detailed information. It was not 
possible to include the data in Table 8.  
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Siddique et al 2006 [21] used a thermostable vaccine produced in Bangladesh, and confirmed its efficacy in goats 
after keeping the vaccine at room temperature (25-30°C) for 14 days. The methodology used for the vaccine is 
the one described in: Chowdhury SMZH, Shukur A, Nasiruddin M, Ara MR, Ferdous KS, Sobhan Z, Habib S, Das BK 
and Litamoi JK (2004). Molecular characterization of PPR virus: Experiential development of PPR thermostable 
vaccine. Annual Research Review Workshop-2004, Bangladesh Livestock Research Institute, Savar, Dhaka, 9-10 
May 2004.  It has not been possible to find that reference, but being Dr Litamoi the last author, it is quite safe to 
assume that it is based on the Xerovac technology.  
In Nigeria, El-Yuguda et al 2014 [22] did a field evaluation of a thermostable vaccine produced with a variation of 
the Xerovac technology.  The vaccine elicited protective immune response in vaccinated goats and vaccinated 
animals resisted challenge to experimental infection with virulent PPR virus. The vaccine maintained good titres 
at room temperature for 8 hours, but dropped after 15 hours.  They also evaluated different routes, and 
concluded that the vaccine could also be given orally.  
 
Thermo-stable vaccine strains 
Another method to improve thermostability of PPR vaccines is the use of thermo-stable vaccine strains in terms 
of their stability at ambient temperature.  In order to achieve intrinsic thermo-resistance in a virus, the native 
virus can be grown successively for many passages at higher temperatures and it may result in an intrinsically 
thermo-resistant virus clonal population. Such an adapted thermo-resistant virus clonal population can be then 
grown at a higher temperature than the usual temperature of 37°C, in thermo-adapted (Ta) cell lines. In this 
approach, the results are largely empirical as they depend on the capability of the virus to resist detrimental 
effect of high temperature. Selection and subsequent propagation of the virus clonal population, their stability, 
and maintenance of their immunogenic potential need to be assessed before considered them as a vaccine 
candidate [23]. 
IVRI in India, have developed two thermostable vaccines: Revati and Jhansi [12], and tested their thermal 
degradation profile. At 37 and 40°C, these thermostable vaccines had a shelf life of 7.62 and 3.68 days, 
respectively, when compared with 1.58 days at 37°C for native Sungri/96 vaccine. The novel thermostable 
vaccines developed were also tested after reconstitution. Different stabilizers were evaluated for these strains 
(see Table 8 and previous comments on stabilizer E).  More details are available for the Jhansi strain, published 
by Balmurugan et al, 2014 [23]:  The lineage IV virus was attenuated up to 50 passages in Ta Vero cells, at which, 
the virus was found sterile, innocuous in mice and guinea pigs and safe in seronegative goats and sheep. The 
developed vaccine was tested for its immunogenicity in goats and sheep by SC inoculation of 100 TCID50 (0.1 
field dose), 103 TCID50 (one field dose) and 105 TCID50 (100 field doses) of the attenuated virus along with 
controls as per OIE described protocols.  
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Table 8:  Comparison of shelf-life (SL) and half-life (HL) of different strains of PPR vaccine, using different stabilisers at different temperatures.  Source: 






LS: Lactalbumin hydrolysate-sucrose; WBM: Weybridge medium; BUGS: buffered gelatin-sorbitol; TD: trehalose dehydrate; E: trehalose, CaCl2 and MgCl2; Tris/Tre: Tris–HCl, 
EDTA, Tween 80, Trehalose; L: Liquid; Ly: Lyophilized. ND: not done.   
 
Strains:  Jhansi 2003 and Revati 2006 are thermos-adapted strains.  
 
NOTE: Attempts to include data from other sources mentioned in the monograph was made, but it was not possible due to the data not being presented in a comparable way. 
LS WBM BUGS 2.5 % TD 5 % TD LS LS E E WBM (L) Tris/Tre (L) WBM (Ly) Tris/Treh (Ly)
Sungri 96 Sungri 96 Sungri 96 Sungri 96 Sungri 96 Jhansi 2003 Revati 2006 Jhansi 2003 Revati 2006 Nig 75/1 Nig 75/1 Nig 75/1 Nig 75/1
SL ND 123 d 239 d 2051 d ND ND ND ND ND
HL ND 30 d 42.25 d 500 d ND ND ND ND ND 22 d 30 d 11 m 10 m
SL 15 d 5 d 12 d 16 d 19 d 23.29 d 22.28 d 25.64 d 22.56 d
HL 4.76 d 1.83 d 2.17 d 4.67 d 4 d 4.68 d 4.9 d 4.62 d 4.81 d
SL 1.58 d ND 1.55 d 1.05 d 1.96 d 7.62 d 6.82 d 6.95 d 5.51 d
HL 17.8 h 10 h 7.79 h 8.57 d 14.07 h 1.76 d 2 d 1.94 d 1.8 d 9 h 21 h 7 h 67 h
SL ND ND ND ND ND 3.68 d 2.61 d 3.48 d 2.29 d
HL ND ND ND ND ND 0.66 d 0.59 d 0.72 d 0.67 d
SL ND ND ND ND ND 43.18 h 23.8 h 39.25 h 40.5 h
HL ND ND ND ND ND 10.6 h 7.12 h 11.1 h 9.68 h
SL 5.72 h 0.56 h 10.8 h 7 h 8.11 h 22.87 h 9.52 h 24.67 h 26.95 h
HL 2.29 h 1.33 h 2.4 h 1.3 h 1.96 h 6.21 h 4.14 h 8.4 h 12.87 h  - 49 h
Stabilizers
Strain
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Animals were assessed for PPRV-specific antibodies 7–28 days post vaccination (dpv) by PPR competitive ELISA 
and serum neutralization tests. The PPRV antibodies were detected in all immunized goats and sheep. The goats 
were challenged with virulent PPRV at 28th dpv (not the sheep), and they were protected. The attenuated 
vaccine did not induce any adverse reaction and provided complete protection even at low dose in goats when 
challenged with virulent virus. There was no shedding and horizontal transmission of the attenuated virus to in-
contact controls. The results indicate that the developed PPR Ta attenuated virus is innocuous, safe, 
immunogenic and potent or efficacious vaccine candidate alternative to the existing vaccines for the protection.  
The paper does not present data on reversion to virulence, but mentions a lack of apparent clinical signs and no 
shedding of the virus in the secretion of goats and sheep during the 3 needle passages indicating that the virus 
has been stably attenuated and the possible reversion to virulence is unlikely.  However, it would be good to see 
the data.  Dr Singh, IVRI Director, was contacted for an update on the status of this candidate.  He said they are 
doing some additional validation trials, and they are expecting to have the product ready in one year. 
 
Inactivated vaccines 
Killed vaccines are not available and, owing to the immunological response to PPRV, would not be fully effective. 
This may also be the reason why no experiments for the development of PPR killed vaccines and for testing their 
protection have been done. The experience of rinderpest eradication showed that killed rinderpest preparations 
(e.g. heated blood or other body fluids from infected animals) were ineffective at giving protection. Additionally, 
some data about the measles vaccines show that the inactivated measles vaccines, besides giving only transient 
protection, could lead to increased virulence of subsequent infection (atypical disease in about 20 % of cases), 
which is one of the reasons why killed measles vaccines are not used [1]. 
 
Main vaccine needs: 
Current vaccines are very good, and similar vaccines were used for the eradication of Rinderpest.  However, it 
would be beneficial to have vaccines that are/have: 
1- Thermostable – this will make logistics of deployment easy 
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Commercial vaccines manufactured in Africa and Asia 
 
The information summarized in Table 9 below, is based on information from The Center for Food Security and 
Public health, Iowa State University (www.cfsph.iastate.edu/vaccines/index.php and Vetvac (www.vetvac.org).   
African manufacturers that were not included in any of the databases have been included: Morocco, Cameroon 
and Kenya. More details have not been gathered, as another consultant has been commissioned to perform this 
task. 
Table 9: Manufacturers of PPR vaccines in Asia and Africa. 
 





Tiankang Biopharmacuetical China Peste des Petits 
Ruminant 
 China 
Hester Biosciences Limited India PPR Vaccine Sungri 96 strain India 
Nepal PPR Vaccine  Nigeria 75/1  
Indian Immunologicals Limited India Raksha PPR  Sungri 96 India 
Institute of Animal Health and 
Veterinary Biologicals [Karnataka]  
India   India 
MSD Animal Health (Merck)  Ovilis PPR  Sungri '96 India,  
Kuwait 
AFRICA 






LANAVET Cameroon Capripestovax Nigeria 75/1 Cameroon 
National Veterinary Institute of Ethiopia  Ethiopia PPR 75/1/LK 6Vero76 Ethiopia 
Veterinary Serum and Vaccine Research 
Institute 
Egypt PPR-TC Vaccine 
Attenuated  
Nigeria 75/1 Egypt 
Kenyan Veterinary Vaccines Production 
Institute 
Kenya Pestevax Nigeria 75/1  
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MCI Sante Animale Morocco Ovipox Nigeria 75/1  
Morocco Lyopox PPR combined with 
Sheep & goat pox 
 
National Veterinary Research Institute Nigeria Peste des Petits 
Ruminants Virus 
Vaccine  
Nigeria 75/1 Nigeria 
Institut Sénégalais de Recherches 
Agricoles [ISRA]  
Senegal PPR Nigeria 75/1 Senegal 
Veterinary Research Institute [Central 
Veterinary Research Laboratories]  
Sudan PPR Nigeria 75/1 Sudan 
Additionally, PPR vaccines are produced in Turkey, Jordan and Pakistan.  
 
 
Commercial vaccines imported into Africa and Asia 
 
The information summarized in Table 10 is based on the questionnaire sent to the Directors of Veterinary 
Services office and regulators of the countries of interest.  For a list of respondents, please see Annex 2. Note 
that some vaccines might have been imported under DVS dispensation, and they are not necessary licensed in 
the country. 
 
Table 10: Commercial PPR vaccines imported into the countries of interest. Replies were not received from 
India, Indonesia, Burkina Faso, Ethiopia, Madagascar, Mozambique, Senegal and South Africa. (Note: The 
disease has never been reported in Madagascar, Malawi, Mozambique and South Africa, therefore no 

























Bangladesh N/A - - - - - - 
Myanmar 
(Burma) 
- - - - - - - 
Nepal - - - - - - - 
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Ethiopia 400,000 80,000 - - 
Kenya - - - - - - - 
Malawi N/A N/A N/A N/A N/A N/A N/A 
Mali N/A N/A N/A N/A N/A N/A N/A 
Rwanda - - - - - - - 
Tanzania** Pestevac Nigeria 
75/1 
Jordan  1,000,000 3,000,000 4,225,000 
Uganda*** Lyopox Nigeria 
75/1 + SGP 
Morocco 1,000,000    
Uganda****  Nigeria 
75/1 
Kenya   100,000  
Zambia - - - N/A N/A N/A - 
 
-   Questionnaire received, no information provided.  
*: That is the name of the vaccine produced in Cameroon, and not in Ethiopia, so there must be some confusion. However, 
both are based on the Nigeria 75/1 strain.  
**: Information provided by the DVS office.  The questionnaire received from the Regulatory Authorities, does not mention 
any PPR imported vaccines.  
***: Information provided by the DVS Office. They also commented that in 2011, they imported 1,558,500 PPR doses from 
Egypt 
****: Information provided by the regulatory authorities 
Other comments: JOVAC, the manufacturer from Jordan was also sent a questionnaire designed for key importers into 
the region.  They confirmed that they export PPR vaccine to Africa and Asia. They did not specify the countries or the 
volumes.  
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• Current use:  Currently, the only commercial combination vaccine, is the one produced by MCI Sante 
Animale in Morocco, called Lyopox PPR. It is a combination vaccine (not a recombinant product), using 
PPR (strain Nigeria 75/1) and Sheep pox (Romania strain).   
• http://www.mci-santeanimale.com/media/produit/pdf/en/prden402590-ang-lyopox-ppr-pdf.pdf  
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The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers.   
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders.  
While efforts have been made to encompass them, the TPP showed in Table 11 below, should be considered a 
proposal, a live document subject to improvements.  
 
Information on current vaccines has been obtained from the datasheet of different products as per links below: 
Ovivax PPR (MCI Sante Animale, Morocco): 
http://www.mci-santeanimale.com/media/produit/pdf/en/prden413237-ang-ovivax-ppr-pdf.pdf  
PPR-VACTM (BVI, Botswana): http://www.bvibw.com/common_up/bvi-new/files/PPR%20-%20VAC.pdf  
PPR Vaccine (Hester, India – Sungri 96 strain): http://www.hesterbiosciences.co.in/ppr-vaccine.php  
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Table 11: Target Product Profile (TPP) PPR vaccine – Proposal: 
 





Immunogen with protective 
antigens against field/wild-type 
PPRV 
Immunogen with protective 
antigens against field/wild-type 
PPRV 
2 Indication for use For active immunization of goat & 
sheep to prevent incidence of PPR   
 
For active immunization of goat & 
sheep to prevent infection of PPR   
3 Recommended species 
 
Goat & sheep Goat & Sheep 
4 Recommended dose 
 
OIE: 100x the lowest dose able to 
induce a 50% immunising response. 
For Nigeria 75/1 strain the required 
minimum titre is 102.5 TCID50 
Volume: 0,5 ml – 1 ml depending on 
manufacturer 
1 ml  
5 Pharmaceutical form 
 
Freeze dried Thermostable at high ambient 
temperatures akin to those 
demonstrated with Xerovac 
6 Route of administration 
 
SC (behind the elbow) 
Other manufacturers recommend 
at mid neck or thigh region.  
SC or IM  
7 Regimen - primary vaccination One dose 
Hester (India) recommends to 
vaccinate after lambing season or 
during onset of breeding season.  
 
One dose 
8 Regimen - booster Annual injection is recommended Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance The 6 PPR vaccine strains appear to 
cross-protect against various global 
PPRVs 
Single vaccine for global use 
10 Recommended age at first 
vaccination 
• One dose at 2 months of age, 
for animals from unvaccinated 
mothers. One dose at 4 months 
1 month of age  
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of age from vaccinated 
mothers. 
• Another manufacturer says one 
dose for animals over 6 
months, and two doses at 2-6 
month interval for animals 
under 6 months. 
Other manufacturer says vaccinate 
at 2-3 months of age, and 
revaccinate after 4 months. 
11 Onset of immunity 
 
3 weeks post vaccination One week following vaccination 
12 Duration of immunity 
 
3 -5 years, practically lifelong Lifelong 
13 Expected efficacy To prevent disease & prevent 
mortality >90% animals 
To prevent infection and 
transmission in 100% of the 
animals.  
14 Expected safety  No abortions in pregnant animals; 
no transmission of vaccine virus to 
others; passive immunity to 
offspring for at least 3 months; no 
recorded reversion to virulence 
No local or systemic post-
vaccination reactions plus all noted 
for currently used PPR vaccines in 
the left column 
15 Withdrawal period 
 
Zero days Nil  
16 Special requirements for animals Only vaccinate healthy animals.  
- Because of the particular 
sensitivity of the pregnant goats to 
injections, it is not recommended to 
vaccinate them, except in 
emergencies. 
Vaccinate all animals 
17 Special requirements for persons  None None 
18 Package size 
 
50 - 100 doses Multiple pack size from 10 doses 
19 Price to end user 
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20 Storage condition and shelf-life as 
packaged for sale 
Store between 2 to 8 °C. Stable for 
2 years.   
 
> 24 months 4-8° C and/or 48 hours 
at 30°C  
21 In-use stability 
 
Use reconstituted vaccine 
immediately. Some manufacturers 
say should not be used more than 2 
hours after reconstitution.  
Use reconstituted vaccine up to 48 
hours & beyond 
22 Other All inoculation equipment should be 
cleaned with water only and 
sterilized in boiling water. 
Antiseptics should not be used.  
Molar solution of magnesium 
sulphate or a buffered physiological 
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Scientific quality: The publications and data from the different research groups, should be carefully evaluated.  
The use of good science and good experimental design with use of proper controls, adequate numbers, suitable 
challenge model, reproduction of results by them and by independent groups, and appropriate analysis has not 
been verified for this monograph.  If any of these projects were to be pursued, a detailed peer review taking into 
account the above considerations is strongly recommended.   
  
Peste des Petits Ruminants | Monograph 02 












[1] EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), 2015. Scientific Opinion on peste des 
petits ruminants EFSA Journal 2015;13(1):3985, 94 pp. doi:10.2903/j.efsa.2015.3985. 
[2] Parida S, Muniraju M, Mahapatra M, Muthuchelvan D, Buczkowski H and Banyard AC. Peste des petits 
ruminants. Vet Microbiol 2015; 181: 90-106. 
[3] Baron J, Fishbourne E, Couacy-Hyman E et al. Development and testing of a field diagnostic assay for 
peste des petits ruminants virus. Transbound Emerg Dis 2014; 61: 390-396. 
[4] Berguido FJ, Bodjo SC, Loitsch A and Diallo A. Specific detection of peste des petits ruminants virus 
antibodies in sheep and goat sera by the luciferase immunoprecipitation system. J Virol Methods 2016; 
227: 40-46. 
[5] Food and Agriculture Organization of the United Nations (FAO) and World Organization for Animal 
Health (OIE). Global strategy for the control and eradication of PPR. 2015. [See link under Other 
resources, page 50]. 
[6] Food and Agriculture Organization of the United Nations (FAO) and World Organization for Animal 
Health (OIE). Global control and eradicaction of peste des petits ruminants - Investing in veterinary 
systems, food security and poverty alleviation. 2015. [See link under Other resources, page 50]. 
[7] Servan de Almeida R, Keita D, Libeau G and Albina E. Control of ruminant morbillivirus replication by 
small interfering RNA. J Gen Virol 2007; 88: 2307-2311. 
[8] Holz CL, Albina E, Minet C et al. RNA interference against animal viruses: how morbilliviruses generate 
extended diversity to escape small interfering RNA control. J Virol 2012; 86: 786-795. 
[9] Diallo A, Taylor WP, Lefevre PC and Provost A. [Attenuation of a strain of rinderpest virus: potential 
homologous live vaccine]. Rev Elev Med Vet Pays Trop 1989; 42: 311-319. 
[10] Martrenchar A, Zoyem N and Diallo A. Experimental study of a mixed vaccine against PPR and capripox 
infection in goats in Northern Cameroon. Small Ruminant Research 1997; 26: 39-44. 
Peste des Petits Ruminants | Monograph 02 






[11] Khan HA, Siddique M, Arshad M et al. Post-vaccination antibodies profile against Peste des petits 
ruminants (PPR) virus in sheep and goats of Punjab, Pakistan. Trop Anim Health Prod 2009; 41: 427-430. 
[12] Sen A, Saravanan P, Balamurugan V et al. Vaccines against peste des petits ruminants virus. Expert Rev 
Vaccines 2010; 9: 785-796. 
[13] Liu F, Wu X, Liu W, Li L and Wang Z. Current perspectives on conventional and novel vaccines against 
peste des petits ruminants. Vet Res Commun 2014; 38: 307-322. 
[14] Saravanan P, Sen A, Balamurugan V et al. Comparative efficacy of peste des petits ruminants (PPR) 
vaccines. Biologicals 2010; 38: 479-485. 
[15] Worrall EE, Litamoi JK, Seck BM and Ayelet G. Xerovac: an ultra rapid method for the dehydration and 
preservation of live attenuated Rinderpest and Peste des Petits ruminants vaccines. Vaccine 2000; 19: 
834-839. 
[16] Asim M, Rashid A and Chaudhary H. Effect ov various stabilizers on titre of lyophilized live-attenuated 
PPR vaccine. Pakistan Vet J 2008; 2008: 203-204. 
[17] Sarkar J, Sreenivasa BP, Singh RP, Dhar P and Bandyopadhyay SK. Comparative efficacy of various 
chemical stabilizers on the thermostability of a live-attenuated peste des petits ruminants (PPR) vaccine. 
Vaccine 2003; 21: 4728-4735. 
[18] Riyesh T, Balamurugan V, Sen A et al. Evaluation of efficacy of stabilizers on the thermostability of live 
attenuated thermo-adapted Peste des petits ruminants vaccines. Virol Sin 2011; 26: 324-337. 
[19] Silva AC, Carrondo MJ and Alves PM. Strategies for improved stability of Peste des Petits Ruminants 
Vaccine. Vaccine 2011; 29: 4983-4991. 
[20] Silva AC, Yami M, Libeau G, Carrondo MJ and Alves PM. Testing a new formulation for Peste des Petits 
Ruminants vaccine in Ethiopia. Vaccine 2014; 32: 2878-2881. 
[21] Siddique MP, Rahman MB, Chowdhury SMZH, Kafi MA and Alam MS. Determination of efficacy of 
thermostable PPR live homologous vaccine incubated at room temperature for 14 days. Bangl J Vet Med 
2006; 4: 43-46. 
[22] El-Yuguda A-D, Baba SS, Ambali AG and Egwu GO. Field trial of a thermostable PPR vaccine in a semi-arid 
zone of Nigeria. World Journal of Vaccines 2014; 4: 1-6. 
[23] Balamurugan V, Sen A, Venkatesan G, Bhanuprakash V and Singh RK. Protective immune response of live 
attenuated thermo-adapted peste des petits ruminants vaccine in goats. Virusdisease 2014; 25: 350-357. 
[24] Qin J, Huang H, Ruan Y et al. A novel recombinant Peste des petits ruminants-canine adenovirus vaccine 
elicits long-lasting neutralizing antibody response against PPR in goats. PLoS One 2012; 7: e37170. 
Peste des Petits Ruminants | Monograph 02 






[25] Wang Y, Liu G, Chen Z et al. Recombinant adenovirus expressing F and H fusion proteins of peste des 
petits ruminants virus induces both humoral and cell-mediated immune responses in goats. Vet 
Immunol Immunopathol 2013; 154: 1-7. 
[26] Herbert R, Baron J, Batten C, Baron M and Taylor G. Recombinant adenovirus expressing the 
haemagglutinin of Peste des petits ruminants virus (PPRV) protects goats against challenge with 
pathogenic virus; a DIVA vaccine for PPR. Vet Res 2014; 45: 24. 
[27] Holzer B, Taylor G, Rajko-Nenow P et al. Determination of the minimum fully protective dose of 
adenovirus-based DIVA vaccine against peste des petits ruminants virus challenge in East African goats. 
Vet Res 2016; 47: 20. 
[28] Rojas JM, Moreno H, Valcarcel F, Pena L, Sevilla N and Martin V. Vaccination with recombinant 
adenoviruses expressing the peste des petits ruminants virus F or H proteins overcomes viral 
immunosuppression and induces protective immunity against PPRV challenge in sheep. PLoS One 2014; 
9: e101226. 
[29] Rojas JM, Moreno H, Garcia A, Ramirez JC, Sevilla N and Martin V. Two replication-defective adenoviral 
vaccine vectors for the induction of immune responses to PPRV. Vaccine 2014; 32: 393-400. 
[30] Chandran D, Reddy KB, Vijayan SP et al. MVA recombinants expressing the fusion and hemagglutinin 
genes of PPRV protects goats against virulent challenge. Indian J Microbiol 2010; 50: 266-274. 
[31] Sinnathamby G, Renukaradhya GJ, Rajasekhar M, Nayak R and Shaila MS. Immune responses in goats to 
recombinant hemagglutinin-neuraminidase glycoprotein of Peste des petits ruminants virus: 
identification of a T cell determinant. Vaccine 2001; 19: 4816-4823. 
[32] Rahman MM, Shaila MS and Gopinathan KP. Baculovirus display of fusion protein of Peste des petits 
ruminants virus and hemagglutination protein of Rinderpest virus and immunogenicity of the displayed 
proteins in mouse model. Virology 2003; 317: 36-49. 
[33] Liu F, Wu X, Li L, Liu Z and Wang Z. Formation of peste des petits ruminants spikeless virus-like particles 
by co-expression of M and N proteins in insect cells. Res Vet Sci 2014; 96: 213-216. 
[34] Liu F, Wu X, Zhao Y, Li L and Wang Z. Budding of peste des petits ruminants virus-like particles from 
insect cell membrane based on intracellular co-expression of peste des petits ruminants virus M, H and 
N proteins by recombinant baculoviruses. J Virol Methods 2014; 207: 78-85. 
[35] Li W, Jin H, Sui X et al. Self-assembly and release of peste des petits ruminants virus-like particles in an 
insect cell-baculovirus system and their immunogenicity in mice and goats. PLoS One 2014; 9: e104791. 
[36] Khandelwal A, Renukaradhya GJ, Rajasekhar M, Sita GL and Shaila MS. Immune responses to 
hemagglutinin-neuraminidase protein of peste des petits ruminants virus expressed in transgenic peanut 
plants in sheep. Vet Immunol Immunopathol 2011; 140: 291-296. 
Peste des Petits Ruminants | Monograph 02 






[37] Hosamani M, Singh SK, Mondal B et al. A bivalent vaccine against goat pox and Peste des petits ruminats 
induces protective immune responses in goats. Vaccine 2006; 24: 6058-6064. 
[38] Ayalet G, Fasil N, Jembere S, Mekonen G, Sori T and Negussie H. Study on immunogenicity of combined 
sheep and goat pox and peste des petits ruminants vaccines in small ruminants in Ethiopia. African 
Journal of Microbiology Research 2012; 6: 7212-7217. 
[39] Chaudhary SS, Pandey KD, Singh RP, Verma PC and Gupta PK. A vero cell derived combined vaccine 
against sheep pox and Peste des Petits ruminants for sheep. Vaccine 2009; 27: 2548-2553. 
[40] Berhe G, Minet C, Le Goff C et al. Development of a dual recombinant vaccine to protect small ruminants 
against peste-des-petits-ruminants virus and capripoxvirus infections. J Virol 2003; 77: 1571-1577. 
[41] Caufour P, Rufael T, Lamien CE et al. Protective efficacy of a single immunization with capripoxvirus-
vectored recombinant peste des petits ruminants vaccines in presence of pre-existing immunity. Vaccine 
2014; 32: 3772-3779. 
[42] Yin C, Chen W, Hu Q et al. Induction of protective immune response against both PPRV and FMDV by a 
novel recombinant PPRV expressing FMDV VP1. Vet Res 2014; 45: 62. 
 
 
Other resources used 
1. Infectious Diseases of Livestock. 2nd Edition. Edited by J A W Coetzer and R C Tustin. Oxford University Press 
Southern Africa. 2004. 
2. The Center for Food Security & Public Health. Iowa State University, USA.  
http://www.cfsph.iastate.edu/Factsheets/pdfs/peste_des_petits_ruminants.pdf    
3. World Organization for Animal Health: OIE Terrestrial Manual. Manual of Diagnostic tests and vaccines for 
terrerstrial animals 2015. Accessed on line. http://www.oie.int/international-standard-setting/terrestrial-
manual/access-online/. 
4. OIE and FAO, 2015. Global strategy for the control and eradication of PPR. (with Annexes)  
http://www.oie.int/fr/PPR2015/doc/PPR-Global-Strategy-avecAnnexes_2015-03-28.pdf 
5. OIE and FAO, 2015. Global control and eradication of peste des petits ruminants – Investing in veterinary 
systems, food security and poverty alleviation. http://www.oie.int/eng/PPR2015/doc/PPR-Advocacy-
EN.pdf  
 
Peste des Petits Ruminants | Monograph 02 






Annex 1: Additional data on disease presence and 
incidence 
Reports to OIE on PPR: 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals. 
 
PPR in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
 
Peste des Petits Ruminants | Monograph 02 






PPR in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
PPR in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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PPR in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
 
 
 
 
 
